ACCESS Newswire·Jul 10, 2026, 8:00 AM ET

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

MIRA Pharmaceuticals announced positive preclinical results for MIRA-55, an oral non-opioid candidate for chronic inflammatory pain.
The company selected a lead oral formulation demonstrating favorable bioavailability, sustained systemic exposure, & reproducible distribution into brain & liver tissues.
These pharmacokinetic findings support the molecule's ability to modulate central pain pathways & peripheral anti-inflammatory activity.
Previous studies showed MIRA-55 normalized pain & reduced inflammation in inflammatory models, outperforming injected morphine & differing from THC.
MIRA-55 demonstrated anxiolytic activity without THC-like central nervous system effects & interacts with cannabinoid receptors via a distinct mechanism.
The U.S. Drug Enforcement Administration determined that MIRA-55 is not a controlled substance.
The company plans to continue evaluating tissue exposure, pharmacodynamic activity, & therapeutic efficacy during further preclinical development.
MIRA is also advancing other candidates including Ketamir-2 for chemotherapy-induced peripheral neuropathy & SKNY-1 for obesity & addiction disorders.